We evaluated CHL1 gene expression in association with known clinical and biological parameters, predictors of NB patients’ survival, using the R2 Genomics Analysis and Visualization Platform and considering data from four independent NB patients’ datasets, namely SEQC [16], Versteeg [14], Lastowska, and Maris [22]. The gene discussed is CHL1; the disease is neuroblastoma.